Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma

Abstract

Abstract. The clinical course of renal cell carcinoma (RCC) can be difficult to predict. In this study we evaluated the prognostic value of anillin and Ki-67 in predicting survival in RCC. Immunohistochemical analysis using anillin and Ki-67 antibodies was performed on tissue microarrays constructed from paraffin-embedded specimens from 152 patients with primary RCC. The mean follow-up time was 90 months. Levels of anillin and Ki-67 staining were correlated with clinical factors, pathological features and survival. Anillin expression in cytoplasmic and nuclear fractions of the RCC cell line 786-O was examined using Western blot analysis. Cytoplasmic anillin immunopositivity was detected in 121 (83%) tumours. Nuclear anillin expression was present in 40 (27%) tumours and increased Ki-67 activity in 98 (66%) tumours. A positive association was found between nuclear anillin and Ki-67 proliferation activity (p=0.005). The mean RCC-specific survival times for anillin immunopositive and immunonegative tumours were 158 (95% CI 143-173) and 109 (78-141) months, respectively, with p=0.03. Increased Ki-67 activity showed a tendency towards a poorer prognosis, although this was not statistically significant. In the Cox regression analysis for cytoplasmic anillin, nuclear anillin or Ki-67 rate, and age, gender, stage and nuclear grade, the only significant factor in RCC-specific survival was stage (p<0.001). Western blot analysis showed anillin expression in both nuclear and cytosolic fractions of the RCC cell line. To conclude, anillin expression can be observed both in the cytoplasm and nuclei in patients with RCC. Cytoplasmic anillin expression is a marker of favourable prognosis in RCC patients.

Systematic construction and validation of an immune prognostic model for lung adenocarcinoma

“…The relationship between carcinoma and cell cycle regulation is well known. ANLN has been shown to be a biomarker of unfavourable prognosis and is related to aggressive tumour phenotypes . Anillin plays a regulatory role in the cell cycle and an important role in the invasion of pancreatic and breast cancers .…”

“…ANLN has been shown to be a biomarker of unfavourable prognosis and is related to aggressive tumour phenotypes. 49 Anillin plays a regulatory role in the cell cycle and an important role in the invasion of pancreatic and breast cancers. 50,51 ANLN has been developed as a prognostic marker based on immunohistochemistry (IHC) and is clinically applicable to hepatocellular carcinoma.…”

Anillin regulates epithelial cell mechanics by structuring the medial-apical actomyosin network

“…Most studies have found that anillin is overexpressed in diverse tumors, and its expression correlates with cancer progression and poor survival rates (Hall et al, 2005; Suzuki et al, 2005; Wang et al, 2016; Idichi et al, 2017; Zhang et al, 2018). However, work examining the subcellular localization of anillin found that nuclear localization of anillin correlates with poor survival rates, whereas cytoplasmic localization of anillin is a marker of favorable prognosis, suggesting that anillin’s localization rather than its expression level is key (Ronkainen et al, 2011; Liang et al, 2015). Our finding that anillin increases tissue stiffness may help explain anillin’s role in tumor progression.…”

“…Although there is little research on how anillin may contribute to the mechanical properties of cancer cells, it is becoming clear that anillin’s function extends beyond cytokinesis. Anillin resides not only in the nucleus of interphase cancer cells, but also in the cytoplasm, and anillin expression can have either positive or negative outcomes for patients depending on the cancer type and anillin’s subcellular localization (Hall et al, 2005; Suzuki et al, 2005; Ronkainen et al, 2011; Liang et al, 2015; Magnusson et al, 2016; Wang et al, 2016; Idichi et al, 2017; Zhang et al, 2018).…”

Dysregulated ANLN reveals immune cell landscape and promotes carcinogenesis by regulating the PI3K/Akt/mTOR pathway in clear cell renal cell carcinoma

“…Our findings from the TCGA-KIRC cohort suggest that ANLN expression may be a prognostic factor for these patients. Better prognosis was associated with renal carcinoma cells expressing ANLN in the cytoplasm [ 51 ]. The results of multivariate analysis were unremarkable; however, univariate analysis revealed that ANLN expression may negatively affect the prognosis of patients with ccRCC.…”